GlobeNewswire by notified

Crocus Delivers the Future of High Precision, High Current Contactless Isolated Current Sense

Share

The CT45x showcases the advantages of TMR sensors to rethink and simplify solutions in the high precision, high current application space

MILPITAS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Crocus Technology Inc., the leading supplier of disruptive TMR (Tunnel Magneto-Resistance) XtremeSense® sensors, today announced the CT45x family of contactless isolated current sensors to enable high precision and high current measurements in a more simplified solution. Unlike existing solutions, the CT45x allows manufacturers to eliminate costly shields, concentrators or cores. The CT452 and CT453 offers contactless 0.7% accuracy, 1 MHz bandwidth, and better than -50 dB immunity to external magnetic fields without additional mechanical components. This combination of performance and accuracy enables customers to reduce their overall product size and weight which enables them to replace large and costly current sense modules with a small and simple solution.

As current requirements have been increasing so have the challenges of accurately measuring high currents, typically >200 A and often up to 2,000 A. Shunt resistors with isolated amplifiers are broadly used but present an issue with I2R losses and tend to be large and costly. Existing magnetic based solutions like Hall Effect and AMR are less accurate and have high temperature drift. The CT45x products are based on XtremeSense TMR technology that delivers the future with a high signal-to-noise ratio (SNR) contactless approach which can scale with the system requirements, high bandwidth and fast response time, common-model field rejection, combined with high accuracy measurements over temperature.

In addition, many applications now require very accurate current measurements in the milliamp range up to the 1,000 A range or more. Often this type of solution involves multiple current sensors to achieve the desired system performance with many design compromises and complexities. Using Crocus’ XtremeSense TMR current sensors allows for a no-compromise and simple solution using a single CT45x sensor which provides a large dynamic range and a high SNR. For example, the CT45x is able to measure down to 500 mA resolution and up to 1,800 A while maintaining better than 0.7% accuracy.

The CT45x offers groundbreaking noise performance, as low as 0.55 mVRMS, to enable applications to sense small current levels and small changes or variations in current through a busbar. This performance is almost 10 times better than existing Hall Effect solutions. This results in a SNR (signal-to-noise ratio) as high as 77 dB for the CT45x measurement which allows the system to process higher resolution data with higher accuracy.

“With the introduction of the CT45x family of contactless current sense products, we now have a complete portfolio of products for our customers from small currents to larger currents,” states Zack Deiri, President and CEO of Crocus Technology. “This product based on Crocus’ cutting-edge TMR technology is the most exciting for us as the benefits of our XtremeSense TMR are addressing the needs of higher current applications that can’t be met with existing solutions without compromises. Crocus is excited to be addressing new high current markets such as BMS, Inverters, DC/DC Converter and many others.”

Product features and performance:

CT450 & CT452 (5 V version) & CT453 (3.3 V version)

Isolated Contactless Current Sensor

Capable of measuring currents from 5 mA to >2,000 A

Total output error ±0.7% Full-Scale

300 ns response time, 1 MHz bandwidth

Available in six different configured field ranges

Protection capability with Over Field Detection (OFD)

Integrated Common Mode Field Rejection (CMFR) with >90% immunity (CT452/3)

Uniform magnetic field sensing (CT450)


Targeting applications in EV Chargers, Battery Management Systems (BMS), DC/DC Converters, 48-V system, Bidirectional Charging and AC/DC Inverters.

The CT450 is available in TSSOP-8 package. The CT452/3 are available in TSSOP-16 package For more information, please visit the product webpage:

CT450 https://crocus-technology.com/products/ct450/

CT452 https://crocus-technology.com/products/ct452/

CT453 https://crocus-technology.com/products/ct453/

About Crocus Technology

Crocus Technology develops and manufactures state-of-the-art magnetic sensors based on its patented XtremeSense® TMR sensor technology. Crocus’ disruptive magnetic sensor technology enables the highest sensitivity, the lowest power consumption and smallest size over a wide temperature range. Crocus is headquartered in Milpitas, California. For more information, please visit http://www.crocus-technology.com.

For more information, please contact:

Crocus Technology
Email: info@crocus-technology.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form